Active Ingredient History
Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles. Oseltamivir is a well tolerated orally active neuraminidase inhibitor which significantly reduces the duration of symptomatic illness and hastens the return to normal levels of activity when initiated promptly in patients with naturally acquired influenza. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Coronavirus Infections (Phase 4)
COVID-19 (Phase 3)
Critical Illness (Phase 2)
Drug Interactions (Phase 1)
Drug Therapy, Combination (Phase 4)
Healthy Volunteers (Phase 2)
Infections (Phase 1)
Influenza A virus (Phase 3)
Influenza in Birds (Phase 2)
Kidney Failure, Chronic (Phase 1)
Lung Diseases (Phase 1)
Lymphoma (Phase 2)
Metabolic Diseases (Phase 4)
Obesity (Phase 1/Phase 2)
Pneumonia (Phase 4)
Pregnancy (Phase 1)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Purpura, Thrombocytopenic, Idiopathic (Phase 3)
Respiratory Tract Infections (Phase 4)
SARS-CoV-2 (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Therapeutic Equivalency (Phase 1)
Thrombocytopenia (Phase 2)
Virus Diseases (Phase 2)
Virus Shedding (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue